268 related articles for article (PubMed ID: 31078911)
21. Systematic identification of the druggable interactions between human protein kinases and naturally occurring compounds in endometriosis.
Jiang L; Tang C; Rao J; Xue Q; Wu H; Wu D; Zhang A; Chen L; Shen Z; Lei L
Comput Biol Chem; 2017 Dec; 71():136-143. PubMed ID: 29096379
[TBL] [Abstract][Full Text] [Related]
22. Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.
Verkhivker GM
Curr Med Chem; 2017; 24(42):4838-4872. PubMed ID: 27719654
[TBL] [Abstract][Full Text] [Related]
23. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
[TBL] [Abstract][Full Text] [Related]
24. Analyzing Kinase Similarity in Small Molecule and Protein Structural Space to Explore the Limits of Multi-Target Screening.
Schmidt D; Scharf MM; Sydow D; Aßmann E; Martí-Solano M; Keul M; Volkamer A; Kolb P
Molecules; 2021 Jan; 26(3):. PubMed ID: 33530327
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors.
Türe A; Kahraman DC; Cetin-Atalay R; Helvacıoğlu S; Charehsaz M; Küçükgüzel İ
Comput Biol Chem; 2019 Feb; 78():227-241. PubMed ID: 30579980
[TBL] [Abstract][Full Text] [Related]
26. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
27. Extending kinome coverage by analysis of kinase inhibitor broad profiling data.
Jacoby E; Tresadern G; Bembenek S; Wroblowski B; Buyck C; Neefs JM; Rassokhin D; Poncelet A; Hunt J; van Vlijmen H
Drug Discov Today; 2015 Jun; 20(6):652-8. PubMed ID: 25596550
[TBL] [Abstract][Full Text] [Related]
28. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
[TBL] [Abstract][Full Text] [Related]
29. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract][Full Text] [Related]
30. High-throughput Docking and Molecular Dynamics Simulations towards the Identification of Novel Peptidomimetic Inhibitors against CDC7.
Makhouri FR; Ghasemi JB
Mol Inform; 2018 Nov; 37(11):e1800022. PubMed ID: 29984527
[TBL] [Abstract][Full Text] [Related]
31. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
32. Use of Protein Kinase-Focused Compound Libraries for the Discovery of New Inositol Phosphate Kinase Inhibitors.
Puhl-Rubio AC; Stashko MA; Wang H; Hardy PB; Tyagi V; Li B; Wang X; Kireev D; Jessen HJ; Frye SV; Shears SB; Pearce KH
SLAS Discov; 2018 Oct; 23(9):982-988. PubMed ID: 29842835
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
34. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
36. Mapping Biological Activities to Different Types of Molecular Scaffolds: Exemplary Application to Protein Kinase Inhibitors.
Dimova D; Bajorath J
Methods Mol Biol; 2018; 1825():327-337. PubMed ID: 30334211
[TBL] [Abstract][Full Text] [Related]
37. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors.
Sun J; Lv PC; Guo FJ; Wang XY; Xiao-Han ; Zhang Y; Sheng GH; Qian SS; Zhu HL
Eur J Med Chem; 2014 Jun; 81():420-6. PubMed ID: 24859762
[TBL] [Abstract][Full Text] [Related]
38. Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity.
Sharlow ER; Mustata Wilson G; Close D; Leimgruber S; Tandon M; Reed RB; Shun TY; Wang QJ; Wipf P; Lazo JS
PLoS One; 2011; 6(10):e25134. PubMed ID: 21998636
[TBL] [Abstract][Full Text] [Related]
39. Identification, structure modification, and characterization of potential small-molecule SGK3 inhibitors with novel scaffolds.
Gong GQ; Wang K; Dai XC; Zhou Y; Basnet R; Chen Y; Yang DH; Lee WJ; Buchanan CM; Flanagan JU; Shepherd PR; Chen Y; Wang MW
Acta Pharmacol Sin; 2018 Dec; 39(12):1902-1912. PubMed ID: 30038340
[TBL] [Abstract][Full Text] [Related]
40. High-throughput screening against ~6.1 million structurally diverse, lead-like compounds to discover novel ROCK inhibitors for cerebral injury recovery.
Gong H; Yuan Z; Zhan L
Mol Divers; 2016 May; 20(2):537-49. PubMed ID: 26700101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
